Published in Osteoporos Int on April 07, 2016
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res (1993) 10.98
Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res (2000) 7.29
Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab (2001) 3.43
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med (2005) 2.60
The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res (2003) 2.50
Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med (2005) 2.47
Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res (2004) 2.07
Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients. Osteoporos Int (2014) 2.03
Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis. Osteoporos Int (2006) 1.79
Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res (2008) 1.78
Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res (2007) 1.75
Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res (2006) 1.58
Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2007) 1.53
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med (2004) 1.51
Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab (2009) 1.35
Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study. J Bone Miner Res (2010) 1.32
The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res (2003) 1.19
"Occult" osteoporotic vertebral fractures: vertebral body fractures without radiologic collapse. Spine (Phila Pa 1976) (2005) 1.05
Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide. Osteoporos Int (2010) 1.04
PINP as an aid for monitoring patients treated with teriparatide. Bone (2010) 0.98
Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study. J Clin Endocrinol Metab (2013) 0.98
Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin (2006) 0.97
An algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatide. Osteoporos Int (2013) 0.90
Determinants associated with bone mineral density increase in response to daily teriparatide treatment in patients with osteoporosis. Bone (2014) 0.90
Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Bone (2006) 0.89
Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis. Osteoporos Int (2013) 0.87
PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporos Int (2014) 0.87
Analysis of daily teriparatide treatment for osteoporosis in men. Osteoporos Int (2015) 0.84
Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study. Curr Med Res Opin (2008) 0.84
Effects of increasing age, dosage, and duration of PTH treatment on BMD increase--a meta-analysis. Calcif Tissue Int (2012) 0.83
Efficacy of the dynamic radiographs for diagnosing acute osteoporotic vertebral fractures. Osteoporos Int (2013) 0.80
Variability in the measured response of bone to teriparatide. Osteoporos Int (2010) 0.79
Usefulness of daily teriparatide treatment in elderly patients over 80 years of age. Osteoporos Int (2016) 0.77
Usefulness of daily teriparatide treatment in elderly patients over 80 years of age. Osteoporos Int (2016) 0.77
Erratum to: A retrospective analysis of nonresponse to daily teriparatide treatment. Osteoporos Int (2016) 0.75